OncoTherapy Science
4564.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Operating income | −¥769m | −¥728m | −¥889m | −¥1.1bn | −¥2.0bn | −¥1.4bn |
| Ordinary income | −¥776m | −¥712m | −¥873m | −¥1.1bn | −¥2.0bn | −¥1.3bn |
| Total assets | ¥2.3bn | ¥840m | ¥507m | ¥949m | ¥2.1bn | ¥2.9bn |
| Net assets / equity | ¥2.1bn | ¥729m | ¥354m | ¥575m | ¥1.7bn | ¥2.6bn |
| EPS (basic) | ¥-2.77 | ¥-3.12 | ¥-4.74 | ¥-5.8 | ¥-12.94 | ¥-8.77 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 174 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 64 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 173 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 64 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 173 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 66 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 173 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 66 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 172 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Cancer Precision Medical Business | ¥806m | −¥56m |
| Research And Development Of Pharmaceutical Products | ¥2m | −¥532m |
| Adjustments & eliminations | — | −¥223m |
| Total | ¥809m | −¥587m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.